Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.35 |
| ▸ | ADA | P00813 | 2/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368044 | 0.90 | AHCY (0.43) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL17358613 | 0.87 | AHCY (0.40) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL16368046 | 0.85 | AHCY (0.41) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL16644536 | 0.84 | ADORA2A (0.54) | AHCYADORA2AADORA2BPI4KAPI4K2B | |
| SCHEMBL16639886 | 0.83 | AHCY (0.41) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL18877330 | 0.79 | ADORA3 (0.49) | ADORA3 | |
| SCHEMBL15070360 | 0.78 | AHCY (0.46) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL17357699 | 0.77 | FAP (0.38) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL18875013 | 0.75 | ADORA3 (0.38) | ADORA2AADORA3 | |
| SCHEMBL25577337 | 0.75 | ADORA2A (0.55) | AHCYADORA2AADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | AHCY 443/4885ADORA2A 57/4885ADORA2B 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.